DE60239535D1 - Diagnose und prognose von brustkrebspatientinnen - Google Patents

Diagnose und prognose von brustkrebspatientinnen

Info

Publication number
DE60239535D1
DE60239535D1 DE60239535T DE60239535T DE60239535D1 DE 60239535 D1 DE60239535 D1 DE 60239535D1 DE 60239535 T DE60239535 T DE 60239535T DE 60239535 T DE60239535 T DE 60239535T DE 60239535 D1 DE60239535 D1 DE 60239535D1
Authority
DE
Germany
Prior art keywords
breast cancer
relates
diagnosis
forecasting
cancer patients
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60239535T
Other languages
English (en)
Inventor
Hongyue Dai
Yudong He
Peter S Linsley
Mao Mao
Christopher J Roberts
T Veer Laura Johanna Van
De Vijver Marc J Van
Rene Bernards
A A Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rosetta Inpharmatics LLC
Original Assignee
Rosetta Inpharmatics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rosetta Inpharmatics LLC filed Critical Rosetta Inpharmatics LLC
Application granted granted Critical
Publication of DE60239535D1 publication Critical patent/DE60239535D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57415—Specifically defined cancers of breast
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G16B25/10—Gene or protein expression profiling; Expression-ratio estimation or normalisation
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • G16B40/30—Unsupervised data analysis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16Z—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS, NOT OTHERWISE PROVIDED FOR
    • G16Z99/00—Subject matter not provided for in other main groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B25/00—ICT specially adapted for hybridisation; ICT specially adapted for gene or protein expression
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B40/00—ICT specially adapted for biostatistics; ICT specially adapted for bioinformatics-related machine learning or data mining, e.g. knowledge discovery or pattern finding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
DE60239535T 2001-06-18 2002-06-14 Diagnose und prognose von brustkrebspatientinnen Expired - Lifetime DE60239535D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US29891801P 2001-06-18 2001-06-18
US38071002P 2002-05-14 2002-05-14
PCT/US2002/018947 WO2002103320A2 (en) 2001-06-18 2002-06-14 Diagnosis and prognosis of breast cancer patients

Publications (1)

Publication Number Publication Date
DE60239535D1 true DE60239535D1 (de) 2011-05-05

Family

ID=26970946

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60239535T Expired - Lifetime DE60239535D1 (de) 2001-06-18 2002-06-14 Diagnose und prognose von brustkrebspatientinnen

Country Status (11)

Country Link
US (5) US7514209B2 (de)
EP (1) EP1410011B1 (de)
JP (2) JP2005500832A (de)
AT (1) ATE503023T1 (de)
AU (1) AU2002316251A1 (de)
CA (1) CA2451074C (de)
CY (1) CY1111677T1 (de)
DE (1) DE60239535D1 (de)
DK (1) DK1410011T3 (de)
PT (1) PT1410011E (de)
WO (1) WO2002103320A2 (de)

Families Citing this family (177)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050123938A1 (en) * 1999-01-06 2005-06-09 Chondrogene Limited Method for the detection of osteoarthritis related gene transcripts in blood
US20040241726A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of allergies related gene transcripts in blood
US20040265868A1 (en) * 1999-01-06 2004-12-30 Chondrogene Limited Method for the detection of depression related gene transcripts in blood
US20040248170A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of hyperlipidemia related gene transcripts in blood
US7473528B2 (en) * 1999-01-06 2009-01-06 Genenews Inc. Method for the detection of Chagas disease related gene transcripts in blood
US20060134635A1 (en) * 2001-02-28 2006-06-22 Chondrogene Limited Method for the detection of coronary artery disease related gene transcripts in blood
US20040248169A1 (en) * 1999-01-06 2004-12-09 Chondrogene Limited Method for the detection of obesity related gene transcripts in blood
US20040241728A1 (en) * 1999-01-06 2004-12-02 Chondrogene Limited Method for the detection of lung disease related gene transcripts in blood
US20030216558A1 (en) * 2000-12-22 2003-11-20 Morris David W. Novel compositions and methods for cancer
AUPR278301A0 (en) 2001-01-31 2001-02-22 Bionomics Limited A novel gene
US7026121B1 (en) * 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US7235358B2 (en) * 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) * 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7171311B2 (en) * 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
CA2451074C (en) * 2001-06-18 2014-02-11 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
US20030104426A1 (en) * 2001-06-18 2003-06-05 Linsley Peter S. Signature genes in chronic myelogenous leukemia
ES2390531T3 (es) * 2001-09-18 2012-11-13 Genentech, Inc. Composiciones y procedimientos para el diagnósitco y tratamiento de tumor
WO2003030725A2 (en) * 2001-10-11 2003-04-17 The Johns Hopkins University Pancreatic cancer diagnosis and therapies
US20040009495A1 (en) * 2001-12-07 2004-01-15 Whitehead Institute For Biomedical Research Methods and products related to drug screening using gene expression patterns
US20030198972A1 (en) * 2001-12-21 2003-10-23 Erlander Mark G. Grading of breast cancer
CN1643163A (zh) * 2002-02-20 2005-07-20 Ncc技术投资私人有限公司 关于癌症诊断的材料和方法
EP2241636A1 (de) 2002-03-13 2010-10-20 Genomic Health, Inc. Genexpressionsprofilierung in einer Biopsie unterzogenem Tumorgewebe
US20050152899A1 (en) * 2002-05-10 2005-07-14 Kinch Michael S. EphA2 agonistic monoclonal antibodies and methods of use thereof
US20040028685A1 (en) * 2002-05-10 2004-02-12 Kinch Michael S. EphA2 monoclonal antibodies and methods of use thereof
JP4585968B2 (ja) * 2002-05-10 2010-11-24 パーデュー・リサーチ・ファウンデーション ＥｐｈＡ２アゴニストモノクローナル抗体およびその使用法
US8008003B2 (en) 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
US20060188889A1 (en) * 2003-11-04 2006-08-24 Christopher Burgess Use of differentially expressed nucleic acid sequences as biomarkers for cancer
WO2004058050A2 (en) * 2002-12-20 2004-07-15 Avalon Pharmaceuticals Amplified cancer target genes useful in diagnosis and therapeutic screening
US20040231909A1 (en) 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US20070149449A1 (en) * 2003-02-14 2007-06-28 Morris David W Therapeutic targets in cancer
DE602004017426D1 (de) * 2003-02-20 2008-12-11 Genomic Health Inc Benutzung von intronischen rna sequenzen zur quantifizierung der genexpression
WO2004079014A2 (en) * 2003-03-04 2004-09-16 Arcturus Bioscience, Inc. Signatures of er status in breast cancer
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
EP1617864A4 (de) * 2003-04-11 2006-06-21 Medimmune Inc Epha2 und nicht-neoplastische hyperproliferative zellstörungen
US7892745B2 (en) * 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20060263813A1 (en) * 2005-05-11 2006-11-23 Expression Diagnostics, Inc. Methods of monitoring functional status of transplants using gene panels
US7306910B2 (en) * 2003-04-24 2007-12-11 Veridex, Llc Breast cancer prognostics
JP2007515945A (ja) * 2003-05-30 2007-06-21 ロゼッタ インファーマティックス エルエルシー キネシン活性の調節因子を同定するための方法
US7604799B2 (en) 2003-06-06 2009-10-20 Medimmune, Llc EphA4 Antibodies
EP1651775A2 (de) * 2003-06-18 2006-05-03 Arcturus Bioscience, Inc. Überleben von patienten mit brustkrebs und dessen wiederauftreten
ES2609234T3 (es) 2003-06-24 2017-04-19 Genomic Health, Inc. Predicción de la probabilidad de recidiva de cáncer
EP1644858B1 (de) 2003-07-10 2017-12-06 Genomic Health, Inc. Expressions-profil-algorithmus und test auf krebsprognose
US20060003391A1 (en) * 2003-08-11 2006-01-05 Ring Brian Z Reagents and methods for use in cancer diagnosis, classification and therapy
US20050112622A1 (en) 2003-08-11 2005-05-26 Ring Brian Z. Reagents and methods for use in cancer diagnosis, classification and therapy
ES2311852T3 (es) * 2003-08-28 2009-02-16 Ipsogen Identificacion de un modelo especifico de la expresion del gen erbb2 en cancer de mama.
GB0320648D0 (en) * 2003-09-03 2003-10-01 Randox Lab Ltd Molecular marker
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
US9856533B2 (en) 2003-09-19 2018-01-02 Biotheranostics, Inc. Predicting breast cancer treatment outcome
AU2004274973A1 (en) * 2003-09-19 2005-03-31 Aviaradx, Inc. Predicting breast cancer treatment outcome
US7504214B2 (en) 2003-09-19 2009-03-17 Biotheranostics, Inc. Predicting outcome with tamoxifen in breast cancer
GB0323226D0 (en) * 2003-10-03 2003-11-05 Ncc Technology Ventures Pte Lt Materials and methods relating to breast cancer diagnosis
EP1892306A3 (de) * 2003-10-06 2008-06-11 Bayer HealthCare AG Verfahren und Kit zur Untersuchung von Krebs
CA2551267C (en) 2003-12-23 2012-05-01 Genomic Health, Inc. Universal amplification of fragmented rna
US20050186577A1 (en) 2004-02-20 2005-08-25 Yixin Wang Breast cancer prognostics
WO2005083429A2 (en) * 2004-02-20 2005-09-09 Veridex, Llc Breast cancer prognostics
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
JP2007527247A (ja) * 2004-03-05 2007-09-27 ロゼッタ インファーマティクス エルエルシー 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
EP2163650B1 (de) 2004-04-09 2015-08-05 Genomic Health, Inc. Genexpressionsmarker zur Vorhersage des Erfolgs von Chemotherapy
WO2005106044A1 (en) * 2004-04-23 2005-11-10 Exagen Diagnostics, Inc. Compositions and methods for breast cancer prognosis
WO2005118879A2 (en) * 2004-06-04 2005-12-15 Arcturus Bioscience, Inc. Identification of tumors
US20120258442A1 (en) * 2011-04-09 2012-10-11 bio Theranostics, Inc. Determining tumor origin
US7587279B2 (en) 2004-07-06 2009-09-08 Genomic Health Method for quantitative PCR data analysis system (QDAS)
TWI661199B (zh) 2004-07-23 2019-06-01 太平洋愛吉生技股份有限公司 檢測膀胱癌之尿液標記物
EP1782315A4 (de) * 2004-07-30 2009-06-24 Rosetta Inpharmatics Llc Prognose für brustkrebspatienten
EP1627923A1 (de) * 2004-08-18 2006-02-22 Het Nederlands Kanker Instituut Mittel und Methoden für den Nachweis und die Klassifizierung von foIllikulären Lymphomen
WO2006029184A2 (en) * 2004-09-08 2006-03-16 Expression Diagnostics, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
JP5184087B2 (ja) * 2004-09-22 2013-04-17 トリパス イメージング， インコーポレイテッド ガンの予後のためのマーカー候補を分析および最適化するための方法およびコンピュータープログラム製品
GB0421838D0 (en) 2004-09-30 2004-11-03 Congenia S R L Cancer markers
US8747867B2 (en) 2004-09-30 2014-06-10 Ifom Fondazione Instituto Firc Di Oncologia Molecolare Cancer markers
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
DK1836629T3 (da) 2004-11-05 2020-05-18 Genomic Health Inc Forudsigelse af respons på kemoterapi ved anvendelse af markører for genekspression
AU2005304878B2 (en) 2004-11-05 2010-07-08 Genomic Health, Inc. Molecular indicators of breast cancer prognosis and prediction of treatment response
CA2592993C (en) * 2004-12-13 2013-06-18 National University Corporation Okayama University Method for detecting methylation in genes and method for examining neoplasm through detecting methylation in genes
US20060183893A1 (en) * 2005-01-25 2006-08-17 North Don A Nucleic acids for apoptosis of cancer cells
WO2006090389A2 (en) * 2005-02-24 2006-08-31 Compugen Ltd. Novel diagnostic markers, especially for in vivo imaging, and assays and methods of use thereof
WO2006110264A2 (en) * 2005-03-16 2006-10-19 Sidney Kimmel Cancer Center Methods and compositions for predicting death from cancer and prostate cancer survival using gene expression signatures
DE102005013846A1 (de) 2005-03-24 2006-10-05 Ganymed Pharmaceuticals Ag Identifizierung von Oberflächen-assoziierten Antigenen für die Tumordiagnose und -therapie
US7608413B1 (en) * 2005-03-25 2009-10-27 Celera Corporation Kidney disease targets and uses thereof
US20090047282A1 (en) * 2005-03-25 2009-02-19 Hideaki Tojo Prophylactic/Therapeutic Agent for Cancer
EP2365092A1 (de) 2005-06-03 2011-09-14 Aviaradx, Inc. Identifikation von Tumoren und Geweben
AU2006254874A1 (en) * 2005-06-08 2006-12-14 Carefusion 303, Inc. System and method for dynamic determination of disease prognosis
EP1946118A4 (de) * 2005-11-10 2009-01-21 Aurelium Biopharma Inc Gewebediagnose für brustkrebs
US8014957B2 (en) * 2005-12-15 2011-09-06 Fred Hutchinson Cancer Research Center Genes associated with progression and response in chronic myeloid leukemia and uses thereof
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
NZ545243A (en) * 2006-02-10 2009-07-31 Pacific Edge Biotechnology Ltd Urine gene expression ratios for detection of cancer
US7888019B2 (en) 2006-03-31 2011-02-15 Genomic Health, Inc. Genes involved estrogen metabolism
US20090098538A1 (en) * 2006-03-31 2009-04-16 Glinsky Gennadi V Prognostic and diagnostic method for disease therapy
WO2008051290A2 (en) * 2006-04-07 2008-05-02 Xdx, Inc. Steroid responsive nucleic acid expression and prediction of disease activity
US7789081B2 (en) * 2006-04-20 2010-09-07 Whirlpool Corporation Modular frame chassis for cooking range
US20080003142A1 (en) 2006-05-11 2008-01-03 Link Darren R Microfluidic devices
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
DE102006027818A1 (de) * 2006-06-16 2007-12-20 B.R.A.H.M.S. Aktiengesellschaft In vitro Multiparameter-Bestimmungsverfahren zur Diagnose und Frühdiagnose von neurodegenerativen Erkrankungen
DE602007013405D1 (de) * 2006-07-14 2011-05-05 Us Government Verfahren zur bestimmung der prognose eines adenokarzinoms
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
US7993832B2 (en) * 2006-08-14 2011-08-09 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
EP2090588A4 (de) 2006-10-23 2010-04-07 Neocodex S L In-vitro-verfahren zur prognose und/oder diagnose von überempfindlichkeit gegen estrogene oder substanzen mit estrogener wirkung
KR100862972B1 (ko) 2006-10-30 2008-10-13 한국과학기술연구원 휘발성 유기 화합물 검색용 바이오마커 및 이를 이용한유해성을 나타내는 휘발성 유기 화합물 검색 방법
WO2008140484A2 (en) * 2006-11-09 2008-11-20 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
WO2008073578A2 (en) 2006-12-08 2008-06-19 Iowa State University Research Foundation, Inc. Plant genes involved in nitrate uptake and metabolism
CA2672270A1 (en) * 2006-12-15 2008-06-26 Gennadi V. Glinksy Treatments of therapy resistant diseases and drug combinations for treating the same
WO2008079269A2 (en) * 2006-12-19 2008-07-03 Genego, Inc. Novel methods for functional analysis of high-throughput experimental data and gene groups identified therfrom
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
US8030060B2 (en) * 2007-03-22 2011-10-04 West Virginia University Gene signature for diagnosis and prognosis of breast cancer and ovarian cancer
US20090062144A1 (en) * 2007-04-03 2009-03-05 Nancy Lan Guo Gene signature for prognosis and diagnosis of lung cancer
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
KR100886937B1 (ko) 2007-06-21 2009-03-09 주식회사 랩 지노믹스 유방암 및 난소암의 예측 또는 진단에 유용한 ｂｒｃａ1,ｂｒｃａ2 유전자 돌연변이
JP5303132B2 (ja) * 2007-09-20 2013-10-02 シスメックス株式会社 がん細胞の存否を判定する方法及び装置
EP2093567A1 (de) * 2008-02-21 2009-08-26 Pangaea Biotech, S.A. Brca1-mRNA-Expressionsebenen zur Vorhersage der Überlebensaussichten von mit neoadjuvanter Chemotherapie behandelten Brustkrebspatienten
US20110053804A1 (en) * 2008-04-03 2011-03-03 Sloan-Kettering Institute For Cancer Research Gene Signatures for the Prognosis of Cancer
ES2338843B1 (es) 2008-07-02 2011-01-24 Centro De Investigaciones Energeticas, Medioambientales Y Tecnologicas Huella genomica de cancer de mama.
WO2010009365A1 (en) 2008-07-18 2010-01-21 Raindance Technologies, Inc. Droplet libraries
EP2159291A1 (de) 2008-09-01 2010-03-03 Agendia B.V. Mittel und Verfahren zur Bestimmung des Tumorzellenanteils in einer Probe
EP2202320A1 (de) * 2008-12-24 2010-06-30 Agendia B.V. Verfahren und Mittel zur Typisierung einer Probe mit Kolorektalkrebszellen
US20100204973A1 (en) * 2009-01-15 2010-08-12 Nodality, Inc., A Delaware Corporation Methods For Diagnosis, Prognosis And Treatment
EP3415235A1 (de) 2009-03-23 2018-12-19 Raindance Technologies Inc. Manipulation von mikrofluidiktröpfchen
EP2241634A1 (de) * 2009-04-16 2010-10-20 Université Libre de Bruxelles Diagnoseverfahren und Werkzeuge zur Vorhersage der Effizienz von gezielten Mitteln gegen IGF-1-Pfadaktivierung bei Krebs
CA2759079A1 (en) 2009-04-20 2010-10-28 Medical College Of Georgia Research Institute, Inc. Breast cancer susceptibility gene gt198 and uses thereof
US8637240B2 (en) * 2009-09-28 2014-01-28 Institute For Systems Biology Use of gene expression signatures to determine cancer grade
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
CA2777417A1 (en) * 2009-10-21 2011-04-28 Basf Plant Science Company Gmbh Method for generating biomarker reference patterns
US20130029926A1 (en) * 2009-11-05 2013-01-31 Myriad Genetics, Inc. Compositions and methods for determing cancer susceptibility
WO2011063274A2 (en) * 2009-11-23 2011-05-26 Genomic Health, Inc. Methods to predict clinical outcome of cancer
WO2011079176A2 (en) 2009-12-23 2011-06-30 Raindance Technologies, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
EP2524055A4 (de) 2010-01-11 2013-06-05 Genomic Health Inc Verfahren zur verwendung von genexpression zur bestimmung der wahrscheinlichkeit des klinischen verlaufs von nierenkrebs
WO2011100604A2 (en) 2010-02-12 2011-08-18 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
JP5725274B2 (ja) 2010-04-22 2015-05-27 国立大学法人大阪大学 乳癌の予後の検査方法
BR112012017649A2 (pt) 2010-04-22 2015-09-15 Toray Industries "método para preparar a rna e de análise de escpressão de gene com uma amostra de rna "
EP3447155A1 (de) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Sandwichassays in tröpfchen
US20140030255A1 (en) * 2010-11-03 2014-01-30 Merck Sharp & Dohme Corp. Methods of predicting cancer cell response to therapeutic agents
US10011876B2 (en) * 2010-11-23 2018-07-03 Krisani Biosciences Pvt. Ltd Method and system for prognosis and treatment of diseases using portfolio of genes
WO2012079059A2 (en) 2010-12-09 2012-06-14 Biotheranostics, Inc. Post-treatment breast cancer prognosis
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
EP2694963B1 (de) 2011-04-01 2017-08-02 Qiagen Genexpressionssignatur für den wnt/b-catenin-signalweg und verwendung davon
WO2012167142A2 (en) 2011-06-02 2012-12-06 Raindance Technolgies, Inc. Enzyme quantification
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
US8748587B2 (en) 2011-06-02 2014-06-10 Novartis Ag Molecules and methods for modulating TMEM16A activities
WO2012177945A2 (en) * 2011-06-21 2012-12-27 Children's Hospital Medical Center Diagnostic methods for eosinophilic esophagitis
US9175351B2 (en) 2011-07-13 2015-11-03 Agendia N.V. Means and methods for molecular classification of breast cancer
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
WO2013025952A2 (en) * 2011-08-16 2013-02-21 Oncocyte Corporation Methods and compositions for the treatment and diagnosis of breast cancer
EP3495817A1 (de) 2012-02-10 2019-06-12 Raindance Technologies, Inc. Molekulardiagnostischer screeningtest
WO2013155567A1 (en) * 2012-04-20 2013-10-24 Mat Malta Advanced Technologies Limited Sex determination genes
WO2013165748A1 (en) 2012-04-30 2013-11-07 Raindance Technologies, Inc Digital analyte analysis
US9045546B2 (en) 2012-05-31 2015-06-02 Novartis Ag Molecules and methods for modulating TMEM16A activities
US9758829B2 (en) 2012-06-22 2017-09-12 Htg Molecular Diagnostics, Inc. Molecular malignancy in melanocytic lesions
WO2014038524A1 (ja) * 2012-09-05 2014-03-13 和光純薬工業株式会社 乳癌の判定方法
EP2986762B1 (de) 2013-04-19 2019-11-06 Bio-Rad Laboratories, Inc. Digitale analyse von analyten
JP2016521979A (ja) 2013-05-30 2016-07-28 ジェノミック ヘルス， インコーポレイテッド 腎臓がんを有する患者に対する再発スコアを計算するための遺伝子発現プロファイルアルゴリズム
CN105706097A (zh) 2013-06-28 2016-06-22 南托米克斯有限责任公司 用于诊断检测的识别的途径分析
CN105745659A (zh) 2013-09-16 2016-07-06 佰欧迪塞克斯公司 利用借助正则化组合多个微型分类器的分类器生成方法及其应用
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
WO2015080585A1 (en) 2013-11-28 2015-06-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Methods for molecular classification of brca-like breast and/or ovarian cancer
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
US10370719B2 (en) * 2014-11-12 2019-08-06 Hitachi Chemical Co., Ltd. Method and device for diagnosing organ injury
US10980519B2 (en) 2015-07-14 2021-04-20 Duke University Systems and methods for extracting prognostic image features
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
WO2017083675A1 (en) 2015-11-13 2017-05-18 Biotheranostics, Inc. Integration of tumor characteristics with breast cancer index
EP3402572B1 (de) 2016-01-13 2022-03-16 Children's Hospital Medical Center Zusammensetzungen und verfahren zur behandlung von allergischen entzündungserkrankungen
US10934590B2 (en) 2016-05-24 2021-03-02 Wisconsin Alumni Research Foundation Biomarkers for breast cancer and methods of use thereof
US10998178B2 (en) 2017-08-28 2021-05-04 Purdue Research Foundation Systems and methods for sample analysis using swabs
US11859250B1 (en) 2018-02-23 2024-01-02 Children's Hospital Medical Center Methods for treating eosinophilic esophagitis
EP3730941A1 (de) * 2019-04-23 2020-10-28 Institut Jean Paoli & Irène Calmettes Verfahren zur bestimmung des molekularen referenztumoraggressivitätsgradienten für ein duktales adenokarzinom des pankreas
US20230330223A1 (en) 2020-04-27 2023-10-19 Agendia N.V. Treatment of her2 negative, mammaprint high risk 2 breast cancer
US20220042106A1 (en) 2020-08-06 2022-02-10 Agendia NV Systems and methods of using cell-free nucleic acids to tailor cancer treatment
US20220042108A1 (en) 2020-08-06 2022-02-10 Agendia NV Systems and methods of assessing breast cancer
CN112927795B (zh) * 2021-02-23 2022-09-23 山东大学 基于bagging算法的乳腺癌预测系统
WO2023224487A1 (en) 2022-05-19 2023-11-23 Agendia N.V. Prediction of response to immune therapy in breast cancer patients
WO2023224488A1 (en) 2022-05-19 2023-11-23 Agendia N.V. Dna repair signature and prediction of response following cancer therapy

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5143854A (en) 1989-06-07 1992-09-01 Affymax Technologies N.V. Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof
US5545522A (en) 1989-09-22 1996-08-13 Van Gelder; Russell N. Process for amplifying a target polynucleotide sequence using a single primer-promoter complex
US6342491B1 (en) * 1991-05-21 2002-01-29 American Home Products Corporation Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
US5677125A (en) 1994-01-14 1997-10-14 Vanderbilt University Method of detection and diagnosis of pre-invasive cancer
WO1995019369A1 (en) * 1994-01-14 1995-07-20 Vanderbilt University Method for detection and treatment of breast cancer
US5578832A (en) 1994-09-02 1996-11-26 Affymetrix, Inc. Method and apparatus for imaging a sample on a device
US5539083A (en) 1994-02-23 1996-07-23 Isis Pharmaceuticals, Inc. Peptide nucleic acid combinatorial libraries and improved methods of synthesis
US5556752A (en) 1994-10-24 1996-09-17 Affymetrix, Inc. Surface-bound, unimolecular, double-stranded DNA
ATE270712T1 (de) 1995-03-17 2004-07-15 Wayne John Cancer Inst Nachweis von melanomenmetastasen unter verwendung eines mehrfachmarker-tests
US6455300B1 (en) 1995-12-08 2002-09-24 Han Htun Method and compositions for monitoring DNA binding molecules in living cells
CA2279361A1 (en) 1997-01-31 1998-08-06 Fred Hutchinson Cancer Research Center Prognosis of cancer patients by determining expression of cell cycle regulators p27 and cyclin e
US6028189A (en) 1997-03-20 2000-02-22 University Of Washington Solvent for oligonucleotide synthesis and methods of use
NO972006D0 (no) * 1997-04-30 1997-04-30 Forskningsparken I Aas As Ny metode for diagnose av sykdommer
US6432707B1 (en) 1997-12-24 2002-08-13 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
US6358682B1 (en) * 1998-01-26 2002-03-19 Ventana Medical Systems, Inc. Method and kit for the prognostication of breast cancer
US6107034A (en) * 1998-03-09 2000-08-22 The Board Of Trustees Of The Leland Stanford Junior University GATA-3 expression in human breast carcinoma
US6218122B1 (en) 1998-06-19 2001-04-17 Rosetta Inpharmatics, Inc. Methods of monitoring disease states and therapies using gene expression profiles
US6203987B1 (en) 1998-10-27 2001-03-20 Rosetta Inpharmatics, Inc. Methods for using co-regulated genesets to enhance detection and classification of gene expression patterns
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
US7648826B1 (en) * 1999-04-02 2010-01-19 The Regents Of The University Of California Detecting CYP24 expression level as a marker for predisposition to cancer
US6647341B1 (en) 1999-04-09 2003-11-11 Whitehead Institute For Biomedical Research Methods for classifying samples and ascertaining previously unknown classes
AU6213600A (en) 1999-07-16 2001-02-05 Rosetta Inpharmatics, Inc. Methods for determining the specificity and sensitivity of oligonucleotides for hybridization
US7013221B1 (en) 1999-07-16 2006-03-14 Rosetta Inpharmatics Llc Iterative probe design and detailed expression profiling with flexible in-situ synthesis arrays
US6271002B1 (en) 1999-10-04 2001-08-07 Rosetta Inpharmatics, Inc. RNA amplification method
AU2596901A (en) 1999-12-21 2001-07-03 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
AU2001229340A1 (en) 2000-01-14 2001-07-24 Millennium Pharmaceuticals, Inc. Genes compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer
WO2002008261A2 (en) * 2000-07-26 2002-01-31 Stanford University Bstp-trans protein and related reagents and methods of use thereof
US7807447B1 (en) 2000-08-25 2010-10-05 Merck Sharp & Dohme Corp. Compositions and methods for exon profiling
US6713257B2 (en) 2000-08-25 2004-03-30 Rosetta Inpharmatics Llc Gene discovery using microarrays
US20030215805A1 (en) 2001-04-20 2003-11-20 Millennium Pharmaceutical, Inc. Novel genes, compositions, kits, and methods for identification, assessment prevention, and therapy of breast cancer
US7171311B2 (en) 2001-06-18 2007-01-30 Rosetta Inpharmatics Llc Methods of assigning treatment to breast cancer patients
CA2451074C (en) 2001-06-18 2014-02-11 Rosetta Inpharmatics, Inc. Diagnosis and prognosis of breast cancer patients
EP1644858B1 (de) 2003-07-10 2017-12-06 Genomic Health, Inc. Expressions-profil-algorithmus und test auf krebsprognose
JP2007527247A (ja) 2004-03-05 2007-09-27 ロゼッタ インファーマティクス エルエルシー 臨床的基準および情報提供性遺伝子セットの組合せを使用する乳癌患者の分類
EP1782315A4 (de) 2004-07-30 2009-06-24 Rosetta Inpharmatics Llc Prognose für brustkrebspatienten
WO2006084272A2 (en) 2005-02-04 2006-08-10 Rosetta Inpharmatics Llc Methods of predicting chemotherapy responsiveness in breast cancer patients

Also Published As

Publication number Publication date
DK1410011T3 (da) 2011-07-18
EP1410011B1 (de) 2011-03-23
US7514209B2 (en) 2009-04-07
WO2002103320A2 (en) 2002-12-27
US20180305768A1 (en) 2018-10-25
JP2005500832A (ja) 2005-01-13
US20090157326A1 (en) 2009-06-18
JP5237076B2 (ja) 2013-07-17
JP2009131262A (ja) 2009-06-18
PT1410011E (pt) 2011-07-25
CY1111677T1 (el) 2015-10-07
CA2451074A1 (en) 2002-12-27
US20030224374A1 (en) 2003-12-04
US20130116145A1 (en) 2013-05-09
EP1410011A4 (de) 2007-08-01
US20110301048A1 (en) 2011-12-08
US9909185B2 (en) 2018-03-06
CA2451074C (en) 2014-02-11
AU2002316251A1 (en) 2003-01-02
WO2002103320A3 (en) 2003-07-31
US7863001B2 (en) 2011-01-04
EP1410011A2 (de) 2004-04-21
ATE503023T1 (de) 2011-04-15

Similar Documents

Publication Publication Date Title
DE60239535D1 (de) Diagnose und prognose von brustkrebspatientinnen
WO2004065545A3 (en) Diagnosis and prognosis of breast cancer patients
WO2006015312A3 (en) Prognosis of breast cancer patients
Bläker et al. The association between mutations in BRAF and colorectal cancer–specific survival depends on microsatellite status and tumor stage
Takeshima et al. Accumulation of genetic and epigenetic alterations in normal cells and cancer risk
Massagué Sorting out breast-cancer gene signatures
Schlomm et al. Clinical significance of p53 alterations in surgically treated prostate cancers
Li et al. BRAF mutation in papillary thyroid carcinoma
Nussinov et al. ‘Latent drivers’ expand the cancer mutational landscape
Schwam et al. Improved prognosis for patients with oral cavity squamous cell carcinoma: Analysis of the National Cancer Database 1998–2006
Cheuk et al. Detection of methylated circulating DNA as noninvasive biomarkers for breast cancer diagnosis
ATE470723T1 (de) Genexpressionsmarker für die prognose von brustkrebs
Andreasen et al. The PRKD1 E710D hotspot mutation is highly specific in separating polymorphous adenocarcinoma of the palate from adenoid cystic carcinoma and pleomorphic adenoma on FNA
Geltzeiler et al. Staging HPV-related oropharyngeal cancer: validation of AJCC-8 in a surgical cohort
Rubin et al. Bioinformatics approach leads to the discovery of the TMPRSS2: ETS gene fusion in prostate cancer
Stern Prostate cancer in US Latinos: what have we learned and where should we focus our attention
Kittaneh et al. Case-based review and clinical guidance on the use of genomic assays for early-stage breast cancer: Breast Cancer Therapy Expert Group (BCTEG)
Brown et al. Extraskeletal myxoid chondrosarcoma: clinical features and overall survival
Liao et al. Relationship between LINC00341 expression and cancer prognosis
Tee et al. Genetic polymorphism of urokinase‐type plasminogen activator is interacting with plasminogen activator inhibitor‐1 to raise risk of cervical neoplasia
Schrijver et al. Promoter hypermethylation profiling of distant breast cancer metastases
Al-Temaimi et al. Reduced FHIT expression is associated with mismatch repair deficient and high CpG island methylator phenotype colorectal cancer
Karim et al. Molecular analysis of V617F mutation in Janus kinase 2 gene of breast cancer patients
Alsofyani et al. Prognostic potential of KLOTHO and SFRP1 promoter methylation in head and neck squamous cell carcinoma
Eggink et al. Less-favourable prognosis for low-risk endometrial cancer patients with a discordant pre-versus post-operative risk stratification